Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-13 am EST			5-day change	1st Jan Change
77.62 ^EUR	-1.87%		-3.41%	-6.17%

Feb. 13	Health Care Up Amid Mixed Earnings - Health Care Roundup	DJ
Feb. 13	European Equities Traded in the US as American Depositary Receipts Decline Friday	MT

SANOFI : Goldman Sachs remains Neutral

Published on 01/15/2026 at 06:28 am EST

MarketScreener with dpa-AFX Analyser

SANOFI

-1.87%

Goldman Sachs analyst James Quigley maintains his Neutral opinion on the stock. The target price is lowered from EUR 95 to EUR 90.

Latest news about Sanofi

Feb. 13	Health Care Up Amid Mixed Earnings - Health Care Roundup	DJ
Feb. 13	European Equities Traded in the US as American Depositary Receipts Decline Friday	MT
Feb. 13	European Midday Briefing : AI Nerves Linger Ahead of U.S. Inflation Data	DJ
Feb. 13	Sanofi's new CEO needs to fix drug pipeline and navigate Trump	RE
Feb. 12	PRESS DIGEST-Financial Times - February 13	RE
Feb. 12	European Stocks Mixed in Thursday Trading; Sanofi Names Belen Garijo as CEO	MT
Feb. 12	European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	MT
Feb. 12	European Stock Markets Mixed Ahead of US Inflation Data
Feb. 12	Jefferies Identifies the Key Challenge for Sanofi's New CEO
Feb. 12	Global markets live: Meta Platforms, Cisco, Amazon, Ford, Applied Materials…
Feb. 12	SANOFI : Gets a Neutral rating from JP Morgan	ZD
Feb. 12	Jefferies Identifies the Key Challenge for Sanofi's New CEO
Feb. 12	European shares retreat from record highs as financials, industrials tumble	RE
Feb. 12	Who is Sanofi's new CEO Belén Garijo?	RE
Feb. 12	Who is Sanofi's new CEO Belén Garijo?	RE

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (79.8%): prescription drugs in the areas of specialty medicine (63.2% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (36.8%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (20.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2024, the group had 52 production sites worldwide. In October 2024, the consumer healthcare products business (Opella) was classified as a discontinued operation. Net sales are distributed geographically as follows: France (4.4%), Europe (17.6%), the United States (48.7%), China (6.5%) and other (22.8%).

Employees

82,878

Sector

Pharmaceuticals

Calendar

Apr. 22 - Q1 2026 Earnings Call

More about the company